Education
About Us
Working with TipRanks
Follow Us
Nuvectis Pharma (NVCT)
NASDAQ:NVCT
NVCT Stock Chart & Stats
$8.86
-$0.26(-4.17%)
At close: 4:00 PM EST
$8.86
-$0.26(-4.17%)
Day’s Range― - ―
52-Week Range$5.55 - $11.52
Previous CloseN/A
Volume31.37K
Average Volume (3M)89.48K
Market Cap
$234.72M
Enterprise Value$203.08M
Total Cash (Recent Filing)$31.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.72
Next Earnings
May 12, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding26,491,701
10 Day Avg. Volume112,705
30 Day Avg. Volume89,483
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)8.94
Price to Sales (P/S)0.00
P/FCF Ratio-10.29
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.36
Forecast
1Y Price Target
$15.67Price Target Upside76.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressInitiation of a Phase 1b trial combining NXP900 with an EGFR inhibitor and a planned ALK combination arm advance the clinical program and create multiple opportunities for meaningful data readouts.
Combination Compatibility And SafetyA clean safety profile and drug‑drug interaction data supporting coadministration with osimertinib and lorlatinib support NXP900's potential as a backbone-compatible combination partner.
Mechanism Of Action And Preclinical EfficacyPreclinical data showing that NXP900 lowers YES1/YAP1 activity and can resensitize EGFR‑ and ALK‑resistant tumor cells provide a clear biological rationale for addressing treatment resistance.
Bears Say
Class Efficacy RiskHistorical failures of Src inhibitors in combination settings due to insufficient target inhibition raise the risk that NXP900 could face similar translational challenges in demonstrating clinical benefit.
Financial Performance ConcernAn earnings per share result slightly below analyst and consensus expectations may increase financial scrutiny and pressure on the company's financing flexibility.
Investor Sentiment And Competitive SkepticismRepeated poor outcomes from prior Src inhibitor combination efforts could dampen investor confidence and make it harder to attract partner interest or secure a premium valuation for the program.
Nuvectis Pharma News
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $5.55 and its highest was $11.52 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Nuvectis Pharma’s market cap is $234.72M.
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s upcoming earnings report date is May 12, 2026 which is in 70 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on Feb 11, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.316 by $0.006.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -0.31.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 26,491,701 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.316. Following the earnings report the stock price went up 0.458%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Currently, no hedge funds are holding shares in NVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvectis Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (76.86% Upside)
$15.67 (76.86% Upside)
Blogger Sentiment
Bearish
NVCT Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
82.74%
12-Months-Change
Fundamentals
Return on Equity
-158.88%
Trailing 12-Months
Asset Growth
105.62%
Trailing 12-Months
Company Description
Nuvectis Pharma
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
NVCT Stock 12 Month Forecast
Average Price Target
$15.67
▲(76.86% Upside)
Technical Analysis
Nkarta
―
Orchestra BioMed Holdings
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
42.07% Insiders
3.65% Mutual Funds
5.52% Other Institutional Investors
43.95% Public Companies and
Individual Investors